OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Kohli on the Challenges of Molecular Classification in Prostate Cancer

September 25th 2019

Manish Kohli, MD, discusses the challenges of molecular classification in prostate cancer.

Dr. Lenz on Updated Results of the CheckMate-142 Trial in mCRC

September 25th 2019

Heinz-Josef Lenz, MD, FACP, discusses updated results from the phase II CheckMate-142 trial in metastatic colorectal cancer.

Dr. Graff on Current Treatments in ESR1-Mutant Breast Cancer

September 25th 2019

Stephanie L. Graff, MD, director of the Breast Program at the Sarah Cannon Cancer Institute of HCA Midwest Health and associate director of the Breast Cancer Research Program at Sarah Cannon Research Institute, discusses current treatments in ESR1-mutant breast cancer.

Dr. Finn on the Rationale for the Phase III KEYNOTE-240 Trial in HCC

September 25th 2019

Richard S. Finn, MD, professor of clinical medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles (UCLA), and Director of the Signal Transduction and Therapeutics Program at the Jonsson Comprehensive Cancer Center at UCLA, discusses the rationale for the phase III KEYNOTE-240 trial in hepatocellular carcinoma (HCC).

Dr. Lyman on Challenges with Biosimilar Policies

September 25th 2019

Gary H. Lyman, MD, MPH, discusses challenges in biosimilar policies.

Dr. Goetz on Adverse Events With Aromatase Inhibitors in Breast Cancer

September 25th 2019

Matthew P. Goetz, MD, discusses adverse events associated with aromatase inhibitors.

Dr. Felip on Immunotherapy Alone or in Combination in Lung Cancer

September 24th 2019

Enriqueta Felip, MD, discusses immunotherapy alone versus immunotherapy plus chemotherapy in patients with lung cancer.

Dr. Rini on Challenges With Biomarkers in RCC

September 24th 2019

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses challenges with biomarkers in renal cell carcinoma (RCC).

Dr. Eradat on the CAPTIVATE Trial in CLL

September 24th 2019

Herbert A. Eradat, MD, associate professor, University of California, Los Angeles Medical Center, discusses unprecedented aspects of the phase II CAPTIVATE trial in chronic lymphocytic leukemia (CLL).

Dr. Mehta on Recent Progress Made in Advanced Gastric Cancer

September 24th 2019

Rutika Mehta, MD, MPH, gastrointestinal medical oncologist, Moffitt Cancer Center, discusses recent progress that has been made in advanced gastric cancer.

Dr. Flaherty on Second-Line Therapy for BRAF-Mutant Melanoma

September 24th 2019

Keith T. Flaherty, MD, discusses treatment beyond frontline therapy for patients with BRAF-mutant relapsed/refractory melanoma.

Dr. Richards on Using PARP Inhibitors in Metastatic Pancreatic Cancer

September 23rd 2019

Donald A. Richards, MD, PhD, discusses the potential benefits of PARP inhibitors in patients with metastatic pancreatic cancer who harbor somatic mutations.

Dr. Smith on Ibrutinib-Based Therapies in CLL

September 23rd 2019

Mitchell R. Smith, MD, PhD, discusses two randomized phase III trials investigating the benefit of ibrutinib-based therapies in patients with chronic lymphocytic leukemia.

Dr. Shah on the Use of Tisagenlecleucel in Pediatric ALL

September 21st 2019

Bijal D. Shah, MD, associate professor, Department of Malignant Hematology, Moffitt Cancer Center, discusses the use of CAR T-cell therapy in patients with pediatric acute lymphoblastic leukemia (ALL).

Dr. Borrello on Selinexor in Penta-Refractory Multiple Myeloma

September 21st 2019

Ivan M. Borrello, MD, associate professor of oncology, Johns Hopkins Medicine, discusses the use of selinexor (Xpovio) in the treatment of patients with penta-refractory multiple myeloma.

Dr. Richards on the Phase III POLO Trial in BRCA-Mutated Pancreatic Cancer

September 21st 2019

Donald A. Richards, MD, PhD, medical oncologist, Texas Oncology, discusses the design and findings of the phase III POLO trial in patients with pancreatic cancer.

Dr. Leach on Brigatinib in ALK-Positive NSCLC

September 21st 2019

Joseph Leach, MD, medical oncologist at Minnesota Oncology, discusses the use of brigatinib (Alunbrig) in ALK-positive non–small cell lung cancer (NSCLC).

Dr. Sotomayor on Differences Between FDA-Approved CAR T-Cell Therapies

September 21st 2019

Eduardo Sotomayor, MD, professor of medicine, Department of Hematology and Oncology, and director, GW Cancer Center, discusses differences between FDA-approved CAR T-cell therapies.

Dr. Wang on CAR T-Cell Therapy Resistance in MCL

September 20th 2019

Michael Wang, MD, discusses CAR T-cell therapy and triple-resistance in mantle cell lymphoma.

Dr. Welslau on REFLECT Interim Safety Analysis in DLBCL

September 20th 2019

Manfred Welslau, MD, discusses the first interim safety analysis in treatment-naïve, CD20-positive diffuse large B-cell lymphoma following the approval of Rixathon, a Sandoz biosimilar for rituximab.